Curing MS is Dr. Greenstein’s life’s work. His background as a neurologist and immunologist coupled with his experience in research (including several years at the National Institute of Health) uniquely qualifies to lead the charge against Multiple Sclerosis through MSRI.
Dr. Greenstein received his medical degree from the University of Cape Town in South Africa and completed his residency in Neurology and his fellowship in Neuropathology at Cleveland Metropolitan General Hospital in Cleveland, Ohio. He then served over five years at the National Institute of Health where he was activity involved in immunology research.
Dr. Greenstein is board certified in Neurology and served for many years as chairman and Professor of Neurology at Temple University School of Medicine, where he also served as the Director of the Multiple Sclerosis Center at Temple University Hospital in Philadelphia, PA. He transitioned to Graduate Hospital and opened his private practice, the Multiple Sclerosis Institute, in order to focus all his efforts exclusively on Multiple Sclerosis.
Within the past three years Dr. Greenstein and the Multiple Sclerosis Research Institute (MSRI) have moved to its current location in Penn Treaty Park Place allowing adequate office and laboratory space to care for patients and research Multiple Sclerosis most effectively. Building on the work of past immunologists, Dr. Greenstein’s research explores the mysteries of T cells, a class of immune cell that seems to hold promise in suppressing dangerous immune responses. Such exploration could lead to new and unique treatments and therapies for MS and other immune diseases.
Dr. Greenstein has made significant progress in identifying the immune mechanism which leads to the development of MS and testing agents which impact the abnormal immune response. Completion of the MSRI laboratory will speed the process by which Dr. Greenstein and his team can FIND, STOP and CURE MS.
Dr. Greenstein is widely published in scientific and neurology journals and has been on the Board of Trustees of the National Multiple Sclerosis Society. Publications include topics ranging from Appropriate Design and Outcome Measures in Multiple Sclerosis Clinical Trials to New Developments in Treatment of Multiple Sclerosis.
Dr. Jeffrey I. Greenstein has always maintained parallel, aggressive scientific pursuits of clinical and basic MS research while caring for and treating MS patients and families for over three decades.
He has participated in groundbreaking clinical research such as the development of Betaseron, the first therapy to treat MS, to the most recent therapy, Tysabri.
Additionally, Dr. Greenstein has actively participated in the education of medical students, residents, and MS specialists as well as other health care professionals and individuals with the disease. All of this experience gives Dr. Greenstein a broad scientific background to foster the development of a unique institution, The Multiple Sclerosis Research Institute.